Evidence map›Paper›PMID 31280388›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2019

The association of low levels of nesfatin-1 and glucagon-like peptide-1 with oxidative stress in Parkinson's disease.

Gülser Karadaban Emir, Yasemin Ünal, Nigar Yılmaz, Kürsad Tosun, Gülnihal Kutlu

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Gülser Karadaban EmirFaculty of Medicine, Department of Neurology, Mugla Sitki Kocman University, Mugla, Turkey. g_karadaban@hotmail.com.ORCID http://orcid.org/0000-0002-3319-1611
Yasemin ÜnalFaculty of Medicine, Department of Neurology, Mugla Sitki Kocman University, Mugla, Turkey.
Nigar YılmazFaculty of Medicine, Department of Biochemistry, Mugla Sitki Kocman University, Mugla, Turkey.
Kürsad TosunSiena College, Laudonville, NY, 12211, USA.
Gülnihal KutluFaculty of Medicine, Department of Neurology, Mugla Sitki Kocman University, Mugla, Turkey.
Muğla University · TRSiena College · US

Funding

Muğla Sıtkı Koçman University Research Projects Coordination Office 15/237
6 · The paper itself

Abstract

aimIn Parkinson's disease (PD), oxidative stress plays a substantial role in degeneration of dopaminergic neurons at the substantia nigra. Recent reports describe nesfatin-1 and glucagon-like peptide-1 (GLP-1) as molecules with neuroprotective property that relieve oxidative stress. In this study, we aimed to determine the blood levels of nesfatin-1, GLP-1 and oxidative stress status in patients with PD. MATERIAL AND

methodForty patients with PD, followed-up at the Department of Neurology of Mugla Sitki Kocman University Training and Research Hospital, were enrolled, as well as 40 age- and sex-matched participants as a control group. We determined and compared nesfatin-1, GLP-1, total antioxidant status (TAS), and total oxidant status (TOS) levels in patients with PD and control group.

resultsThe mean GLP-1 and nesfatin-1 values of patients with PD were lower than those of the control group, whereas their mean TOS value was higher. The mean TAS values, on the other hand, did not reveal any significant difference between the patient and the control groups.

conclusionThe lower nesfatin-1 and GLP-1 levels, in addition to higher TOS levels, in patients with PD compared to those of control group suggest that the neuroprotective effects of these molecules might be related to the oxidative processes. Further studies are required to search for the impact of abovenamed molecules on the treatment option and the likelihood that they may slow down disease progression.

Indexed as

AgedAged, 80 and overFemaleGlucagon-Like Peptide 1HumansMaleMiddle AgedNucleobindinsOxidative StressParkinson DiseaseGlucagon-Like Peptide 1NUCB2 protein, humanNucleobindinsGLP-1Nesfatin-1Oxidative stressParkinson’s disease

Identifiers

PMID31280388
OpenAlexW2954822122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.